TAIWANESE HEALTH AND RESEARCH DELEGATION VISIT PARATUS CLINICAL TRIAL SITE IN CANBERRA Visit fosters greater collaboration and experience of clinical trial execution in public and private health settings best practice
With
Matt Clacy,
Founder & Chief Commercial Officer
Paratus Clinical
Dr Amber Leah,
Principal Investigator & Medical Director
Paratus Clinical
Professor Chun-Jen Huang,
Dean of Office of Human Research
Taipei Medical University & Taipei Municipal Wanfang Hospital
Taiwan
Professor Pin-Kuei Fu,
Director, Clinical Research Center
Taichung Veterans General Hospital
Taiwan
AUSTRALIAN HEALTH JOURNAL SEGMENT
Filmed in Canberra | September 2025
In late August 2025, a Taiwanese delegation comprising government officials from the Taiwanese FDA, various governmental groups, and physicians and researchers from across Taiwan, visited Paratus Clinical’s trial site in Canberra. Their objective was to explore both the differences and similarities between the clinical research ecosystems of Taiwan and Australia.
Throughout the discussions, the delegation learned about the processes involved in initiating research, the regulatory hurdles that must be navigated, and the practicalities of conducting clinical trials in both public and private sectors.
Paratus Clinical specialises in a range of clinical trials, from Phase I to Phase III, including vaccine studies and treatments across primary care areas such as asthma, diabetes, and cardiometabolic health, as well as outpatient specialties like dermatology and oncology.
The conversations also addressed the distinctions between inpatient and outpatient care, focusing on startup timelines, regulatory requirements, and patient recruitment strategies. Notably, the delegation found a reassuring number of similarities in clinical practice between the two countries.
Matt Clacy, recognised the potential benefit of fostering greater collaboration between public and private sectors in Australia, a practice that is more prevalent in Taiwan and advantageous for patient care and the healthcare system overall.
Source: Written by AUDIENCED
-
GP lens on Aboriginal health and COVID-19
The COVID-19 pandemic rolled through 2020 and the first half of 2021 without major lockdowns in regional communities, however recently that changed. The concern is now on vaccination rates in communities across Australia.
First Nation Aboriginal communities are at greater risk of outbreaks and transmission with low vaccination rates because of supply issues and changing advice rather than hesitancy.
-
Physiotherapy approach to jaw & facial pain ties with dental expertise
Darron Goralsky is the Founder, CEO and Clinical Director of Melbourne TMJ & Facial Pain Centre, one of Australia’s leading multidisciplinary clinics dedicated to the assessment and management of temporomandibular disorders (TMD) and craniofacial pain.
-
Investments to address health inequities in Prostate Cancer Care
Income, education, geographical location, and discrimination based on ethnicity, race, gender and sexual orientation, are only a fraction of factors that can negatively affect a person’s quality of cancer care. This is defined as the “equity gap” and it’s costing people their lives.
Timed to coincide with World Cancer Day 4th February 2025, Movember announced prostate cancer investment of $5.5 million. Eighteen grants (16 proposals and 2 community development grants) are slated to directly tackle inequities in prostate cancer care. The funding will be over three years with the grants spread across five countries – six in Canada, five in the United Kingdom, three in Australia, three in the United States and one in Ireland – each having a specific focus population and care area.
